Preclinical studies have identified several potential targets for chordoma drug treatment, e.g., mTOR, PI3K, PDGFR, VEGFR, and EGFR (4, 12), some of which have been evaluated in single-agent clinical trials. Here, EGFR is linked to chordoma.